Blurbs

Leerink Partners Maintains a Buy Rating on Aligos Therapeutics (ALGS)

In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Aligos Therapeutics (ALGSResearch Report), with a price target of $7.00. The company’s shares closed last Tuesday at $2.90, close to its 52-week low of $2.11.

According to TipRanks.com, Ruiz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.4% and a 41.7% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

Currently, the analyst consensus on Aligos Therapeutics is a Moderate Buy with an average price target of $9.00, implying a 221.4% upside from current levels. In a report issued on March 11, Cowen & Co. also maintained a Buy rating on the stock with a $15.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Aligos Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.54 million and GAAP net loss of $33.12 million. In comparison, last year the company had a GAAP net loss of $34.42 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).

Read More on ALGS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More